16 results
8-K
EX-99.2
ABOS
Acumen Pharmaceuticals Inc
14 May 24
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
7:35am
Pathology 20 Tau Pathology: pTau181 pTau217 Neuronal Injury: Total tau Synaptic Injury: Neurogranin VAMP2 Amyloid Pathology: A 42/40 Astrocytic … Activation: GFAP Biomarkers from cerebrospinal fluid and plasma capture neuronal, synaptic, and axonal injury and reflect the cumulative outcome of different
8-K
EX-99.1
j6v4hrts
19 Mar 24
Corporate Presentation March 2024 1
8:05am
8-K
EX-99.1
f1ho9x d7
12 Jan 24
Corporate Presentation January 2024 1
8:42am
8-K
EX-99.1
79h1z3k4s8gz
8 Jan 24
Regulation FD Disclosure
8:33am
10-K
zsglf31aj0 l0po
28 Mar 22
Annual report
4:51pm
10-Q
wqc0 1gq4
16 Aug 21
Quarterly report
4:51pm
424B4
cdjs8uo845gwx3u3h
2 Jul 21
Prospectus supplement with pricing info
4:09pm
S-1/A
ir3edn2i
24 Jun 21
IPO registration (amended)
8:17am
S-1
vxx hna03yraxqk
9 Jun 21
IPO registration
5:02pm
DRS/A
1tm3ml21ju627kgivp
14 May 21
Draft registration statement (amended)
12:00am
DRS
63kuzz8
12 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next